Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14321910 | 0.98 | KMT2A (0.43) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL27484546 | 0.77 | ACHE (0.45) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL85389 | 0.77 | SLC6A9 (0.42) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL16759363 | 0.74 | SLC6A9 (0.46) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL6510613 | 0.74 | OPRD1 (0.41) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL6510618 | 0.74 | OPRD1 (0.41) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL48800 | 0.74 | OPRM1 (0.48) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL72466 | 0.74 | OPRM1 (0.48) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL5695024 | 0.74 | OPRM1 (0.48) | KMT2AOPRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL6843039 | 0.74 | OPRM1 (0.53) | KMT2AOPRM1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111117136-B | Cable material | 温州大学 | 2022-06-07 | — | — | CN | claimed |
| CN-111117136-A | Cable material | 温州大学 | 2020-05-08 | — | — | CN | claimed |
| CN-103517907-B | Volution isoxazolines derivative as antiparasitic | 硕腾服务有限责任公司 | 2016-07-06 | — | — | CN | claimed |
| CN-103517907-A | Spirocyclic isoxazoline derivatives as antiparasitic agents | PFIZER | 2014-01-15 | — | — | CN | claimed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-11932633-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-115650893-A | Synthesis method of 1-benzhydrylazetidin-3-one | 南通华祥医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115650893-A | Synthesis method of 1-benzhydrylazetidin-3-one | 南通华祥医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-111117136-B | Cable material | 温州大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-1185213-C | Azetidine derivatives, preparation thereof and pharmaceutical compositions | AVENTIS PHARMA SA (FR) | 2005-01-19 | — | — | CN | disclosed |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-08 | — | — | US | disclosed |
| CN-1149191-C | Azetidine derivatives, Preparation and medicines containing them | ���ĵ�˹ҩ��ɷ�����˾ | 2004-05-12 | — | — | CN | disclosed |
| WO-2004024730-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
| CN-1423633-A | Azetidine derivatives, process for their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA SA (FR) | 2003-06-11 | — | — | CN | disclosed |
| CN-1316991-A | Azetidine derivatives, preparation and medicines containing them | AVENTIS PHARMA SA (FR) | 2001-10-10 | — | — | CN | disclosed |
| US-4200628-A | ANTIBIOTICS, BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1980-04-29 | — | — | US | disclosed |
| EP-0001643-A2 | Aminoglycoside derivatives, process for their manufacture, pharmaceutical compositions and carboxylic acids | SHIONOGI & CO., LTD. (JP) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | KMT2A 612/4885OPRM1 4387/4885CHRM2 2735/4885 |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CYP19A1, CRH, CYP17A1 | KMT2A 3722/4885OPRM1 43/4885CHRM2 3412/4885 |
| US-11932633-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KMT2A 2081/4885OPRM1 4750/4885CHRM2 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.